Last year, media reports mentioned that Intas had emerged as a strong contender to acquire Mallinckrodt unit in a deal estimated between $1...

This comes as US President Donald Trump has declared opioid addiction a public health emergency in the US and drugmakers have found themsel...

Trumping bigger rivals Aurobindo, Intas shot into the limelight on Wednesday, scooping up Teva's assets in the UK and Ireland in a $764 mil...

With the acquisition of Teva’s products, sold through erstwhile Actavis’ operations, Intas is set to emerge as a top player in the UK gener...

With a net worth of $23.6 billion, up $2.6 billion from last year, RIL Chief Mukesh Ambani topped the list for the eighth consecutive year.

Private school students in India do not outperform their counterparts in public schools, claims a new study by a Michigan State University ...

Private equity firm ChrysCapital is buying an additional stake in Intas Pharmaceuticals for Rs 300 crore after the Ahmedabad-based drug mak...

Although the stake could not be be confirmed, the pre-IPO deal will increase ChrysCapital's holding in the company to over 15% from 11.3% c...

3 PE firms are vying for a minority stake in generic drugmaker Intas Pharmaceuticals, two people familiar with the development told ET.

Intas Pharma plans to raise Rs 750-800 cr through IPO that will help it raise fresh funds for acquisitions besides allowing PE investor Chr...

Many are adopting an arguably unusual route: a B-school programme.